Showing 3631-3640 of 6977 results for "".
- Almirall Presents Early-Stage Pipeline Progress for Tirbanibulinhttps://practicaldermatology.com/news/Almirall-Presents-Early-Stage-Pipeline-Progress-Tirbanibulin/2471540/Almirall, S.A. presented five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, including new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and progress of its early-stage asset LAD191, a high-affinity monoclonal antib
- Treat the Whole Patient: Enhancing Care in Pediatric Alopecia Areatahttps://practicaldermatology.com/news/enhancing-care-for-pediatric-alopecia-patients/2471536/Understanding and treating pediatric alopecia areata (AA), and its impact on the emotional and social lives of children and young people, was the subject of a presentation by dermatologist Brittany Craiglow, MD, PhD, FAAD. Addr
- Analysis: Biosimilars Show Comparable Effectiveness to Humira in Psoriasishttps://practicaldermatology.com/news/analysis-biosimilars-show-comparable-effectiveness-to-humira-in-psoriasis/2471496/Adalimumab biosimilars Amjevita and Imraldi showed similar effectiveness to Humira for the treatment of psoriasis in both new users and patients switching from Humira, according to an analysis of the British Association of Dermatologists Biologics and Immunomodulato
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- Analysis: Nicotinamide Not Linked to Elevated MACE Riskhttps://practicaldermatology.com/news/study-nicotinamide-not-linked-to-mace-risk/2471380/Results from a new retrospective cohort study suggest nicotinamide exposure was not associated with an increased risk of major adverse cardiovascular events (MACE). The analysis included data from 13,108 patients in the Vanderb
- EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Carehttps://practicaldermatology.com/news/effisayil-2-data-suggest-unmet-needs-in-generalized-pustular-psoriasis-care/2471250/Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). The analysis, presented as a poster at Masterclas
- New Option for Molluscum Expected Soonhttps://practicaldermatology.com/news/New-Option-Molluscum-Expected-Soon/2471226/Perhaps the most important measure a dermatologist can take after diagnosing a patient with molluscum is to reassure them that it is not a big deal, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at Winter Clinical Hawaii 2025 in Waikoloa Village, Hawaii.
- Nemolizumab Approved by European Commission for Moderate-to-severe Prurigo Nodularishttps://practicaldermatology.com/news/nemolizumab-approved-european-commission-for-moderate-to-severe-prurigo-nodularis/2471164/Nemolizumab has been approved by the European Commission for the treatment of moderate-to-severe prurigo nodularis, according to an announcement from Galderma. The approval of the monoclonal antibody (marketed as Nemluvio) fol
- Analysis: Hydrating Ointment Rivals Steroid Cream in Eczema Severity Reductionhttps://practicaldermatology.com/news/analysis-hydrating-ointment-rivals-steroid-cream-in-eczema-severity-reduction/2471140/New research suggests a petrolatum and panthenol-based ointment (HO) was as effective as 0.1% triamcinolone acetonide in urea cream (TAU) in reducing the severity of mild-to-moderate chronic hand eczema (CHE). Researchers includ
- Guselkumab Effective in Psoriasis Regardless of Prior Treatment History: Studyhttps://practicaldermatology.com/news/guselkumab-effective-regardless-of-prior-treatment-history-study/2471126/Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials. The study looked